药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Gedivumab
The risk or severity of adverse effects can be increased when Gedivumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bleselumab
The risk or severity of adverse effects can be increased when Bleselumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Nemolizumab
The risk or severity of adverse effects can be increased when Nemolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Mitazalimab
The risk or severity of adverse effects can be increased when Mitazalimab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Suvratoxumab
The risk or severity of adverse effects can be increased when Suvratoxumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Asunercept
The risk or severity of adverse effects can be increased when Asunercept is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ponezumab
The risk or severity of adverse effects can be increased when Ponezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Zolbetuximab
The risk or severity of adverse effects can be increased when Zolbetuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Utomilumab
The risk or severity of adverse effects can be increased when Utomilumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Telisotuzumab vedotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tigatuzumab
The risk or severity of adverse effects can be increased when Tigatuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tezepelumab
The risk or severity of adverse effects can be increased when Tezepelumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Frovocimab
The risk or severity of adverse effects can be increased when Frovocimab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Abrilumab
The risk or severity of adverse effects can be increased when Abrilumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ipafricept
The risk or severity of adverse effects can be increased when Ipafricept is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tafasitamab
The risk or severity of adverse effects can be increased when Tafasitamab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Apomab
The risk or severity of adverse effects can be increased when Apomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Gremubamab
The risk or severity of adverse effects can be increased when Gremubamab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pateclizumab
The risk or severity of adverse effects can be increased when Pateclizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dalantercept
The risk or severity of adverse effects can be increased when Dalantercept is combined with Belantamab mafodotin.